Singapore: Wuxi Biologics, a wholly owned subsidiary of China-based WuXi PharmaTech, recently announced that it has begun the construction of a new $150 million biologics manufacturing facility in Wuxi city China. The new facility will be the world's largest mammalian cell culture manufacturing facility using disposable bioreactors.

When completed, the new plant will support WuXi's strong biologic pipeline and enable the company to maintain its position as the leading biologics player in the world.

The construction is expected to be completed by January 2017 and will house fourteen 2000L disposable bioreactors for fed-batch cell culture and two 1000L bioreactors for perfusion runs.

"Investment in this state-of-the-art biologics commercial facility of the future is another milestone for WuXi Biologics," said Dr Ge Li, chairman and CEO of WuXi PharmaTech. "This project continues to strengthen WuXi's capabilities in integrated biologics discovery, development, and manufacturing services. We maintain the highest quality standards to expedite global development of biologics for both international clients and Chinese companies."

Last year, WuXi completed the construction of state-of-the-art biologics clinical drug substance and drug product manufacturing facilities in Wuxi city, the first in China, that met cGMP standards of the United States, the European Union, and China.